by United Pompe | Jan 18, 2016 | News
Myozyme Produced at the 2000 L Bioreactor Scale to Receive Accelerated Approval Date: November 17, 2008 New PDUFA Date Set for February 28, 2009 Genzyme Corporation (Nasdaq: GENZ) today announced that the FDA plans an Accelerated Approval for Myozyme® (alglucosidase...
by United Pompe | Jan 18, 2016 | News
Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
by United Pompe | Jan 18, 2016 | News
Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study
by United Pompe | Jan 18, 2016 | News
January 2008 US Myozyme Supply Update In April 2007, Genzyme implemented measures to manage the limited supply of Myozyme® (alglucosidase alfa) in the United States in order to ensure uninterrupted treatment for as many patients as possible. Since April, both the...
by United Pompe | Jan 18, 2016 | News
Amicus Therapeutics and Shire plc Enter Into $440 Million ex-US Licensing Agreement
